ABEMACICLIB

Brand name:

• Verzenio®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

Change to existing listing (Category 2)

Comment:

--

Submission sponsor:

Eli Lilly Australia Pty Ltd

Other PBAC consideration:

• ABEMACICLIB
• ABEMACICLIB

Submission received for:

November 2023 PBAC meeting

Opportunity for consumer comment:

Open 26/07/2023 and close 20/09/2023 (see PBS Website)

PBAC meeting:

Held on 01/11/2023

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

11/12/2023

Lodgement of required documentation:

18/12/2023

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 08/02/2024

Status:

Finalised

Government processes:

Commenced on 12/02/2024

Medicine listed on the PBS:

01/05/2024 (see PBS schedule)

---